Clinical Trial on the Mixture of G, C and S in Treatment of Patients With RCC

Phase 2 Completed 40 enrolled Spanish Oncology Genito-Urinary Group

NaSingle-groupOpen-labelTreatment

Summary

Main Objective: To evaluate progression-free survival in patients with unresectable renal cell carcinoma (RCC) treated with a combination of gemcitabine, capecitabine, and sorafenib.

Timeline

Start: 2006-11
Primary completion: 2008-04
Completion: 2008-12

Publications

Bellmunt J, Trigo JM, Calvo E, Carles J, Perez-Gracia JL, Rubio J, Virizuela JA, Lopez R, Lazaro M, Albanell J. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). Lancet Oncol. 2010 Apr;11(4):350-7. doi: 10.1016/S1470-2045(09)70383-3. Epub 2010 Feb 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Capecitabine	Small molecule	500 mg/m2	Intravenous
Subject	Capecitabine	Small molecule	650 mg/m2	Intravenous
Subject	Gemcitabine	Small molecule	1000 mg/m2	Intravenous
Subject	Sorafenib	Small molecule	400 mg	Oral

Clinical Trial on the Mixture of G, C and S in Treatment of Patients With RCC

Summary

Timeline

Publications

Drugs

Indications